Objective: to identify the continuance of sleeping difficulty and medication use in a cohort of older Australian women from baseline to 3-year follow-up and to explore the relationship between these factors and health-related quality of life scores, falls and other health care use. Method: a 3-year longitudinal survey of 10,430 Australian women aged 70-75 years at baseline. These women were participants in the Australian Longitudinal Study on Women's Health randomly selected from the Australian Medicare database. Results: a majority of women (63%) endorsed one or more items related to sleeping difficulty at 3-year follow-up: 33% reported one item only, 16% reported two or three items, and 14% reported more than three items; 4,194 (42.4%) reporting 'waking in the early hours', 2,592 (26.0%) 'taking a long time to get to sleep', 2,078 (21.0%) 'sleeping badly at night', 1,072 (10.8%) 'lying awake most of the night' and 1,087 (11.0%) 'worry keeping you awake'. Total scores on the Nottingham Health Profile sleep sub-scale ranged from 0-100 and were skewed to the right. The median score was 12.57. There was a strong statistical association between reporting sleeping difficulty at baseline and at follow-up. A total of 1,532 (15%) women reported use of sleeping medication at follow-up and women were 6.5 times more likely to report use if they also reported any item of sleep difficulty. There was a moderate level of agreement (88%, k=0.56) between taking sleeping medication within 4 weeks before the baseline survey and within 4 weeks before follow-up. On multivariate analysis, sleeping difficulty at baseline was negatively associated with general health perceptions, emotional role limitations and general mental health sub-scales of the Short-Form-36 Health Survey at follow-up; the use of sleep medication at baseline was negatively associated with physical functioning, bodily pain, vitality, social functioning and general mental health Short-Form-36 sub-scale scores. The use of sleep medication was also significantly associated with falls, accidents, and health care utilisation. Conclusion: sleeping difficulty is a common and persistent complaint among older women and is strongly associated with use of sleeping medications. Both behaviours are negatively associated with health status.
Introduction
Difficulty sleeping is common in older people [1] [2] [3] [4] [5] and frequently attributed to age related physiological changes in circadian rhythms and sleep architecture. Compared with younger adults, older people have less slow-wave sleep (stage 3-4) and less total sleep time [6, 7] . Older people also have more fragmented sleep, waking more frequently and lying awake for long periods.
Although sleep disturbances increase with ageing, changes in sleep pattern do not necessarily lead to symptoms of sleep disturbance and complaints of insomnia [8] . Further, the increased prevalence of comorbidity with ageing, has made the relationship between ageing, per se, and sleeping difficulties, unclear [9] .
Population studies [9] [10] [11] report varied prevalence of sleeping difficulties in a variety of populations, with notable increases in prevalence with age [1, 3, 5] . Morgan et al. report that insomnia is experienced by one in three individuals, is more likely among those with mental and physical problems, is particularly common among women, and (in both sexes) is characterised by problems of sleep onset and sleep maintenance [12] . Other research indicates that poor sleep among older adults may be a prodromal symptom for underlying physical and or psychiatric illness [13] , as well as a possible precursor [14, 15] .
Illness and medication use, psychological symptoms including depression, low levels of physical activity and poor sleep hygiene are the most frequently cited risk factors for insomnia [9] . For example, symptoms such as pain and dyspnoea can interfere with sleep onset and sleep maintenance, and medications such as diuretics and bronchodilators have been shown to trigger insomnia [6] .
Poor sleep quality among older people may also lead to increased consumption of sedatives and hypnotics, which may lead to adverse consequences such as drowsiness, confusion, ataxia, dizziness, and impaired motor coordination [17] [18] [19] [20] . Increased risk of falling and fall-related fractures are other serious consequences, reported in up to three times more users than non-users of sleeping medication [18, 21] . Older people are particularly predisposed to these adverse effects due to physiological changes associated with ageing which lead to changes in pharmacokinetic processes (absorption, distribution, metabolism, and excretion) [18] .
Analysis of baseline data from 12,624 communitydwelling women aged 70-75 years who were participants in the Australian Longitudinal Study on Women's Health (ALSWH) identified strong independent statistical relationships between self-reported sleeping difficulty and health-related quality of life, and between use of sleeping medications and quality of life [22] . Approximately 50% of older women in the ALSWH reported some degree of difficulty sleeping, and approximately 17% reported difficulty sleeping often. The adjusted means for the Short Form-36 (SF-36) health survey sub-scale scores were significantly lower with each category of sleeping difficulty ('often', 'sometimes', 'rarely' and 'never') and were significantly lower among the 18% of women who reported using sleeping medication within 4 weeks prior to study. Similarly, the higher the SF-36 physical and mental health summary scores, the lower the odds of women reporting sleeping difficulty or medication use [22] .
The aim of this study is to explore the continuance of sleeping difficulty and medication use in this cohort of women at 3-year follow-up including the relationship between these factors and health-related quality of life scores, falls and other health care use.
Methods
The ALSWH aims to examine the relationships between biological, psychological, social and lifestyle factors and women's physical and emotional health, as well as their use of and satisfaction with health care services [23, 24] . The study is designed to track the health of women over a period of up to 20 years. The three main cohorts were aged 18-23, 45-50 and 70-75 at baseline in 1996. This present study involves those of the 12,624 participants aged 70-75 at 1996 who contributed data to the first follow-up survey undertaken in 1999.
The original ALSWH study sample of women was drawn from the database of the Health Insurance Commission (HIC). The HIC is the universal provider of basic health insurance and, theoretically, involves all women in Australia (including non-residents). The sample was stratified to over-represent women from rural and remote areas; these women are represented in twice their usual proportions. In this study, 40% of the sample were drawn from urban areas, 54% from rural areas, and 6% from remote areas.
Women were sent written invitations to take part in the study in March 1996, beginning with the completion of an omnibus-style questionnaire on a broad range of health issues. The Dillman protocol for postal surveys [25] was followed but without telephone contact (such contact was precluded by the statutory regulations covering the HIC sampling frame).
Similar procedures were employed at follow-up except that women who did not return their surveys after two reminders were telephoned and invited to complete a short telephone interview which consisted of only selected questions from the survey. Systematic approaches were employed to track participants who had changed address between baseline and follow-up [26] .
The baseline questionnaire
The baseline questionnaire included 260 items measuring biological, psychological, social and lifestyle factors, along with physical and emotional health, use of, and satisfaction with, health care services. Wherever possible, previously validated items and/or scales were used. Scales included the well-known SF-36 [27] to measure health related quality of life; the Duke Social Support Index [28, 29] ; the Australian Nutritional Screening Initiative questionnaire [30] and the Hwalek-Sengstock Elder Abuse Scale [31] . A 21-item scale measured life events over the previous 12 months [32] ; co-morbid conditions and symptoms; and, items related to health care use and medication use. Basic demographic data were collected.
To measure sleeping difficulty, women were asked to respond either 'none', 'rarely', 'sometimes', or 'often' to the question: 'In the past 12 months, have you had difficulty sleeping?' To measure sleeping medication use, response categories were 'yes' or 'no' to the question: 'During the past 4 weeks have you taken any medications to help you sleep (e.g. Normison, Mogadon etc.)?'
The follow-up questionnaire
The follow-up questionnaire was similar in format and content to the baseline questionnaire with the exception that the 5-item sleep sub-scale of the Nottingham Health Profile (NHP) [33] and one other item ('worry keeping you awake at night') were used to further measure sleeping problems. There were additional items relating to falls and accidents within the previous 12 months ('had a fall to the ground', 'been injured as a result of a fall', 'needed to seek medical attention for an injury from a fall', 'had any other injury from an accident at your home', and 'broken or fractured any bone/s').
Statistical analysis
Logistics regression models were used to identify the continuation of sleeping difficulty at 3-year follow-up. Kappa was used to measure agreement between the use of sleeping medications at baseline and follow-up. Due to left skewness of the SF-36 scores, power transformation of 1.5 was applied to make the scores approximately symmetrical. Multiple linear regression models were then used to analyse the relationship between SF-36 scores at follow-up and sleeping difficulty at baseline, while adjusting for baseline SF-36 scores, use of sleeping medications at baseline, symptoms, co-morbidity, life events and age.
Adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated for each item relating to falls and accidents, health care utilisations at follow-up for women who had sleeping difficulty at baseline while adjusting for prior incidence, use of sleeping medications at baseline, symptoms, co-morbidity, life events (except falls) and age. Women who never had sleeping difficulty at baseline formed the reference group for the OR. These analyses were repeated with respect to the use of sleeping medications at baseline while adjusting for the sleeping difficulty at baseline, symptoms, co-morbidity, non-fall life events and age. All analyses were conducted in SAS [34] .
Results
A detailed description of the 12,624 participants in the baseline study has been reported elsewhere [24] . A total of 9,510 women completed the full follow-up survey by mail, and 920 women completed the short telephone version. The response rate for the follow-up survey was 90.6% (n=10,430). Table 1 shows the characteristics of the women in the study.
Scores on the NHP sleep sub-scale ranged from 0-100 and were skewed to the right. The median score was 12.57. Thirty-seven percent of women reported 'no' to all NHP sleep sub-scale items, 33% reported one item only, 16% reported 2 or 3 items, and 14% reported more than 3 items. Responses to individual items provide more detail on the types of difficulty reported with 4,199 women (42.4%) reporting 'waking in the early hours', 2,592 (26.0%) 'taking a long time to get to sleep', 2,078 (21.0%) 'sleeping badly at night', and 1,072 (10.8%) 'lying awake most of the night' (See Figure 1) . Although not part of the sleep sub-scale and additional NHP item 'worry keeping you awake' was included for face validity, and 1,087 (11.0%) of women reported this was a problem. Table 2 list the odds of reporting sleeping difficulty at follow-up for each category of frequency of sleeping difficulty at baseline. The strong association indicates that self-reported sleeping difficulty was a persistent condition among women in the cohort. Compared with women who never had sleeping difficulty at baseline, the odds of reporting sleeping difficulty at follow-up increased with the frequency of sleeping difficulty at baseline.
The fifth item of the NHP sleep sub-scale is the use of sleeping medications. In this study 1,532 (15%) women reported use of sleeping medication at follow-up. Of the 1,665 women who reported use of sleeping medication at baseline, 1,005 (60%) women reported use of sleeping medication at follow up. There was a moderate level of agreement (88%, k=0.56) between taking sleeping medication within 4 weeks before the baseline survey and within 4 weeks before follow-up indicating that the use of these medications is a persistent and stable behaviour. Compared with women who had no sleeping difficulty at follow-up, women with sleep difficulty on each of the items of NHP were more likely to take sleeping medication at follow-up (OR between 1.6-3.0). Women who experienced any of the NHP items were 6.5 times more likely to take sleeping medication at follow-up than those who had not experienced any sleeping difficulties (Table 3) . Figure 2 shows the unadjusted means and 95% CI for SF-36 scores at baseline and follow-up. Women with sleeping difficulty at baseline had lower mean scores for all the eight dimensions of SF-36 than those with no sleeping difficulty. Similar trends were also present for those taking sleeping medication at baseline. Table 4 shows multiple regression models for power transformed SF-36 scores at follow-up. The signs of the coefficients and P-values reflect the direction of association and the statistical significance respectively. Sleeping difficulty at baseline was negatively associated with SF-36 scores adjusted for prior SF-36 scores. However when the SF-36 scores were adjusted for prior SF-36 scores, symptoms, co-morbidity, life events and age at baseline, sleeping difficulty at baseline was only negatively associated with general health perceptions, emotional role limitations and general mental health. 
Problems of sleep for older women
Similarly the use of sleep medication at baseline was negatively associated with all the eight dimensions of SF-36 at follow-up after adjustment for prior SF-36 scores. After adjusting for the other confounding factors physical functioning, bodily pain, vitality, social functioning and general mental health were significantly lower in women who had used sleep medication at baseline. The adjusted OR and 95% CI for falls, accidents, and health care utilisation, for sleep difficulty and the use of sleep medication at baseline are shown in Table 5 . Sleeping medication, but not sleeping difficulty, was significantly associated with falls, doctor consultations and days in hospital after adjustment for confounding factors.
Discussion
This study aimed to identify the prevalence and continuance of sleeping difficulty and medication use among a cohort of older Australian women, and to identify associated health outcomes. The study has the advantages of a large national cohort of women, and collection of data over two time points with very little loss to follow-up. Limitations however, include the single item measure of sleep disturbance at baseline, and a generic self-report measure of sleeping medication use. It is suspected that sleeping medication use may be underreported by the women in the study. For those women who do report medication use, it is unclear whether they are using long or short acting benzodiazepines, or some other medication with hypnotic or sedative properties. In Australia, however, short acting benzodiazepines are the most commonly used class of hypnotic medications [35] .
Difficulty sleeping was commonly and persistently reported by the older women in this study, with waking in the early hours being the most commonly reported manifestation. Further, this difficulty does not appear to be an entirely benign complaint, but associated with significant reduction in the women's quality of life. In longitudinal analyses, reported difficulty sleeping was associated with negative health outcomes as measured by the SF-36 health related quality of life profile. While much of this reduction in quality of life appears to be accounted for by associated symptoms, comorbidity, age, or life events, the association between sleeping difficulty and 'emotional role limitation' and 'general mental health' remained significant event after adjustment for these factors.
However, while sleeping difficulty of itself appears to have negative impact on quality of life, 'treatment' of this symptom with medication does not appear to be an effective measure for the women in the study. A total of 1,532 (15%) of women reported sleeping medication at follow-up and women were most likely to use medications if they reported they were 'sleeping badly at night' (OR 3.5) or 'taking a long time to get to sleep' (OR 3.0). Women were less likely to use medication for 'waking in the early hours'.
While long acting hypnotics should never be prescribed in the elderly, it is recommended that short acting medications (such as benzodiazepines) be prescribed for no more than 4 weeks to avoid problems of tolerance and dependence [36] . However in this study there was strong statistical agreement between use of sleeping medications at baseline and use at follow-up indicating that the women are on these medications for the long term. This finding of long-term use of sleeping medications has been reported in other studies. In the Netherlands, for example it was found that 17% of older people use psychotropics (mainly benzodiazepines) for longer than 6 months [37] . In Australia, the 1995 National Health Survey found 91.4% of people aged 65 and over who had been taking benzodiazepines had been using for 6 months or more [35] . Morgan and Clarke found that one-third of people studied continued to use hypnotics over 4 years of observation [38] . In this present study, the use of medications at baseline was associated with lower quality of life scores for physical functioning, and general mental health even after adjustment for symptoms, comorbidity, age and life events. One of the more commonly reported life events was 'fall with injury' which may in itself have been related to the long-term use of sleeping medications. The period prevalence of falls at follow-up was higher for women reporting medication use at baseline, and remained marginally significant after adjustment for symptoms, comorbidity and non-fall life events.
This increased risk in association with falls has been well documented in other studies [18, 21] . In a metaanalysis of the association between benzodiazepine use and falls, for one or more falls the pooled OR was 1.48 (95% CI 1.23-1.77) [21] . Other health risks have also been suggested. For example, Benzodiazepines are most commonly implicated in admissions hospitalisation due to adverse drug reactions and such reactions account for 17% of all geriatric hospital admissions [39] . Use of hypnotics has also been shown to be associated with cognitive decline [17] and excess mortality [40] .
Given that sleep disturbance is of itself associated with poor quality of life among older women, and that medication use does not appear to be an ideal solution, what are the treatment alternatives? Appropriate management of sleeping difficulty obviously depends on the underlying cause, and it is important to recognise that chronic insomnia has many causes [41] . Behavioural interventions provide a simple, safe and effective alternative to drug therapy [42] [43] [44] and appear to produce more sustained effects [41] . In a recent study, Morin et al. [45] demonstrated that older patients with long-term insomnia treated with cognitive behavioural therapy had significant and sustained quality of life gains over a 2-year follow-up period. These gains were not observed in the comparison group treated with short-term benzodiazepines.
Other alternatives to medication include reassurance, sleep hygiene such as limited use of nicotine, caffeine, and alcohol, regular exercise, avoidance of day time naps, avoidance of heavy meals before sleep, and relaxation techniques [13, 46, 47] . Medication review is also a pillar in the effective management of sleep disturbance [48] .
Difficulty sleeping is a symptom that should be taken seriously among older women, because of its impact on quality of life, because it may be a prodroma for serious physical and psychological illness, and because of the associated use of sleeping medicines. Indeed insomnia has now been recognised as a global priority by the World Health Organisation who recognise an ongoing need to understand the causes and impacts of insomnia as well as how best to disseminate effective and safe interventions [48] .
Older women are the biggest users of sedatives, tranquillisers or hypnotics [49, 50] and, although problems with their use is well recognised within medical literature, benzodiazepines are among the most common inappropriate prescriptions for older people [51] (J. E. Byles et al., unpublished). In Australia, the prevalence of use of benzodiazepines has been stable since 1994 and 1998 [52] . However, a recent Australian study found that health professionals and community members do not believe that the use of benzodiazepines is Table 4 . any longer a problem [53] indicating that there is systematic under-recognition of the problems of sleeping medication use.
Conclusion
This study demonstrates that sleeping difficulty and sleeping medication use are not only common, but also persistent and long-term problems among older women. These two factors are significantly associated with negative health outcomes and should be a key part of health promotion practice and clinical care.
Key points
. Sleeping difficulty is a common complaint among older women. . Sleeping difficulty can be a persistent complaint among older women. . Sleeping difficulty for older women is strongly associated with use of sleeping medications. . Sleeping difficulty and sleeping medication use for older women are both negatively associated with health status. 
